SubsidieMeestersPAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).
ATXA Therapeutics aims to advance NTP42, a novel drug for pulmonary arterial hypertension, through Phase II trials and licensing to accelerate market entry and diversify its drug portfolio.
Projectdetails
Introduction
ATXA Therapeutics has developed NTP42, a disruptive new drug for pulmonary arterial hypertension (PAH) and related cardiopulmonary (heart & lung) diseases. NTP42 blocks the thromboxane receptor, a target at the root cause of PAH and related diseases.
Treatment Efficacy
By treating all clinical hallmarks in both the lungs and heart, NTP42 offers a game-changing solution for PAH, leading to its rapid adoption once marketed. ATXA’s Phase I clinical trial showed that NTP42 is safe and highly efficacious in humans.
Future Plans
With EIC Blended Finance and VC co-investment, ATXA will undertake a Phase II trial on NTP42 in PAH.
- We will then secure a licensing deal with a pharma to accelerate NTP42 to the PAH market.
- Projected sales are expected to exceed $1B at 5 years post-launch, with royalty returns to ATXA.
Diversification and Growth
With the proceeds of the licensing deal, we will diversify the uses of NTP42 and pipeline drugs to treat other priority target diseases. This will also enable growth, creating over 100 full-time equivalents (FTEs) and transforming ATXA into a major European pharma with a diversified diseases and drugs portfolio.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 4.181.504 |
Tijdlijn
| Startdatum | 1-1-2023 |
| Einddatum | 31-12-2023 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ATXA THERAPEUTICS LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer careNectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology. | EIC Accelerator | € 2.499.998 | 2024 | Details |
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market. | EIC Accelerator | € 2.498.816 | 2024 | Details |
APAC – the first targeted therapy for peripheral arterial occlusive disease.Aplagon is developing APAC, a targeted therapy for advanced peripheral arterial occlusive disease, aiming to improve safety and efficacy in clinical studies to address high morbidity and mortality rates. | EIC Accelerator | € 2.099.387 | 2022 | Details |
Acceleration of the world’s first autotaxin inhibitor for the treatment of pancreatic cancer (PDAC)iOnctura aims to accelerate clinical trials for IOA-289, a novel autotaxin inhibitor targeting pancreatic cancer, to improve treatment outcomes and attract further investment. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)Palobiofarma aims to develop PBF-680, a first-in-class adenosine receptor antagonist, to treat COPD, targeting disease progression and seeking €30M for further clinical trials. | EIC Accelerator | € 2.476.106 | 2022 | Details |
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care
Nectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology.
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)
The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market.
APAC – the first targeted therapy for peripheral arterial occlusive disease.
Aplagon is developing APAC, a targeted therapy for advanced peripheral arterial occlusive disease, aiming to improve safety and efficacy in clinical studies to address high morbidity and mortality rates.
Acceleration of the world’s first autotaxin inhibitor for the treatment of pancreatic cancer (PDAC)
iOnctura aims to accelerate clinical trials for IOA-289, a novel autotaxin inhibitor targeting pancreatic cancer, to improve treatment outcomes and attract further investment.
Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)
Palobiofarma aims to develop PBF-680, a first-in-class adenosine receptor antagonist, to treat COPD, targeting disease progression and seeking €30M for further clinical trials.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Transcription Factor Gene Therapy for BradyarrhythmiasPacingCure's TRACTION project aims to optimize and validate BradyTx-01, a gene therapy for cardiac pacing dysfunctions, ensuring safety, efficacy, and a pathway to commercialization. | EIC Transition | € 2.499.968 | 2023 | Details |
Pushing Boundaries in Pre-clinical Aortopathy ResearchThis project aims to unravel mechanisms of syndromic thoracic aortic aneurysm and develop effective therapies using patient-derived aorta-on-a-chip models for pre-clinical research. | ERC Starting... | € 1.494.848 | 2024 | Details |
Targeting the Imidazoline I1 receptor as a novel treatment for AtherosclerosisImnovAth aims to develop a novel therapy targeting a microbiota-derived metabolite to enhance atherosclerosis treatment efficacy and advance towards clinical trials and commercialization. | ERC Proof of... | € 150.000 | 2024 | Details |
TraffikGene-Tx: Targeted Peptide Carriers for RNA DeliveryTraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs. | EIC Transition | € 2.498.963 | 2023 | Details |
Human Antibody-enabled Cardiovascular Personalized TheranosisABCardionostics aims to develop a multi-marker PET/MRI system using human antibodies to personalize treatment and improve diagnosis of atherosclerosis in vulnerable patients. | EIC Pathfinder | € 3.639.665 | 2024 | Details |
Transcription Factor Gene Therapy for Bradyarrhythmias
PacingCure's TRACTION project aims to optimize and validate BradyTx-01, a gene therapy for cardiac pacing dysfunctions, ensuring safety, efficacy, and a pathway to commercialization.
Pushing Boundaries in Pre-clinical Aortopathy Research
This project aims to unravel mechanisms of syndromic thoracic aortic aneurysm and develop effective therapies using patient-derived aorta-on-a-chip models for pre-clinical research.
Targeting the Imidazoline I1 receptor as a novel treatment for Atherosclerosis
ImnovAth aims to develop a novel therapy targeting a microbiota-derived metabolite to enhance atherosclerosis treatment efficacy and advance towards clinical trials and commercialization.
TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery
TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.
Human Antibody-enabled Cardiovascular Personalized Theranosis
ABCardionostics aims to develop a multi-marker PET/MRI system using human antibodies to personalize treatment and improve diagnosis of atherosclerosis in vulnerable patients.